Experimental and investigational · Research guide

MOTS-c for dogs: an exercise-related signal is not an exercise replacement

Mouse performance results make this mitochondrial peptide interesting. Human exercise measurements and canine treatment claims need to stay separate.

The takeaway

Nara’s take.

MOTS-c connects mitochondrial signalling with metabolism and physical function in a scientifically interesting way. The evidence does not yet establish that administering it improves fitness or healthy ageing in dogs.

How it may work

What makes this peptide unusual

MOTS-c is a mitochondrial-derived peptide investigated for effects on metabolic regulation and cellular stress responses. Foundational experiments linked it with glucose handling and metabolic homeostasis in preclinical systems.

That creates a plausible connection to ageing because energy regulation and the ability to respond to stress change with age. It does not mean that supplying the peptide recreates all the benefits of physical activity, which acts through many tissues and pathways at once.

Sources: [1], [2]

What the research shows

What the performance study actually tested

A 2021 study reported improved physical performance and late-life physical capacity after MOTS-c administration in mice. The same paper included human observations of the body's own MOTS-c response to exercise.

Those are not equivalent experiments. Measuring an endogenous signal after people exercise is not evidence that injecting that signal improves human fitness. Neither component is a treatment trial in dogs, and neither supplies a validated canine dose or safety profile.

Sources: [2]

Nara's interpretation

The interesting next question is functional

Nara would like to know whether a characterized intervention can preserve a dog's useful capacity: comfortable walking, recovery and participation in daily life. A metabolic marker is helpful only insofar as it supports a meaningful and safe outcome.

A convincing next study would distinguish trained from untrained animals, specify the intervention and compare it with appropriate control care. Otherwise claims that a peptide makes exercise unnecessary are doing more work than the evidence.

Evidence informing this guidance: [1], [2]

Nara's practical guidance

What this means for your dog

MOTS-c remains an experimental research topic, not a substitute for suitable movement, food or diagnosis of declining exercise tolerance. This guide supplies no injection instructions, dosing cycle or procurement recommendation.

The burden of an experimental product includes uncertain identity and exposure, administration, monitoring and the possibility of overlooking a treatable cause of weakness. A canine programme would need explicit safety oversight and functional endpoints. Until then, the honest position is that the mechanism is worth following while a practical dog benefit remains unestablished.

Evidence informing this guidance: [1], [2]

Follow the evidence

Sources and review notes.

Primary studies, clinical guidance and explicitly labelled sponsor disclosures. A mechanism, an observational association and a treatment result are different kinds of evidence.

Editorial research update: 2026-09-24. These guides build on Nara’s existing source records and a fresh check of accessible primary abstracts, full texts and official pages. This is not an exhaustive systematic review or a new independent clinical review. The evidence assessment retains its own date and status. Practical examples are Nara’s interpretation, not validated treatment protocols.

[1] 2015 · Mouse, rodent and human biological samples/cell systems · Primary mechanistic and mouse intervention study
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Changhan Lee et al.. Cell Metabolism.
10.1016/j.cmet.2015.02.009; PMID 25738459
Foundational MOTS-c biology and mouse metabolic intervention evidence.
[2] 2021 · Mouse and human observational physiology · Primary mouse intervention and human physiological study
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Joseph C Reynolds et al.. Nature Communications.
10.1038/s41467-020-20790-0; PMID 33473109
Reports improved physical performance and late-life physical capacity in mice; human component measures endogenous exercise responses rather than exogenous treatment efficacy.

Keep reading

Connected questions.

Exercise

Volume, intensity, and variety of loading across a dog's week.

Urolithin A

A gut-derived postbiotic studied for mitophagy and muscle function.

NAD+ precursors

NMN and NR, studied for declining NAD+ availability with age.

Open Nara’s evidence assessment

The guide above explains the topic. This separate record preserves the accepted claim, confidence, limitations and safety context. Publishing an article does not upgrade the science or turn an experimental intervention into a recommendation.

Nara’s evidence view

Clinical-trial context only

PreliminaryNon-canine preclinical evidenceVery low confidence

The claim we’re evaluating

Exogenous synthetic MOTS-c improves clinically meaningful metabolic or physical-function outcomes in dogs.

Nara’s interpretation

MOTS-c is a credible signaling-biology research target with reproducible-looking metabolic and physical-performance effects in several mouse experiments, but that is not yet canine therapeutic evidence. Nara should distinguish endogenous MOTS-c biology from administration of a synthetic peptide and should not describe rodent metabolic or exercise findings as demonstrated canine healthspan benefit. At present, exogenous MOTS-c belongs in legitimate research rather than routine owner-directed use.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

How we reached this view

What the evidence shows

MOTS-c is a mitochondrial-derived signaling peptide, and controlled mouse studies report effects on insulin resistance, diet-induced obesity, skeletal-muscle metabolism, exercise performance, and late-life physical capacity. Human work in the key exercise paper measured changes in endogenous MOTS-c after exercise rather than demonstrating benefit from administering MOTS-c to people. No peer-reviewed canine intervention study was identified in the targeted search. FDA's 2026 evidence review likewise found no human administration studies and concluded that effectiveness evidence for nominated metabolic, musculoskeletal, and longevity uses was confined to in-vitro and rodent models, with major pharmacology and safety gaps.

Important limitations

No peer-reviewed canine administration or clinical-outcome study was identified.
The strongest intervention evidence is from mice rather than dogs or humans.
Human exercise-associated increases in endogenous MOTS-c are observational physiology and are not evidence that exogenous synthetic MOTS-c improves outcomes.
Mouse findings span several outcomes and regimens and should not be collapsed into one claim of general anti-aging efficacy.
FDA's review identified missing dose-response information for important preclinical effects and uncertainty regarding the peptide's molecular targets.
Human exposure, clinical pharmacokinetics, immunogenicity, chronic toxicity, reproductive toxicity, carcinogenicity, and long-term safety remain inadequately characterized.

What would change Nara’s view

What would strengthen our view

Independent replication of the preclinical metabolic and functional effects across laboratories and animal models.
Characterized pharmacokinetic and toxicology studies establishing biologically relevant exposure and safety in dogs.
Randomized canine studies measuring meaningful metabolic or physical-function outcomes rather than pathway biomarkers alone.
Human intervention trials demonstrating that exogenous MOTS-c produces clinically meaningful effects, which would improve translational plausibility while still not constituting canine evidence.

What could weaken our view

Independent failures to reproduce the reported mouse metabolic or physical-performance effects.
Evidence that pharmacologically administered MOTS-c cannot maintain relevant exposure because of rapid degradation or other pharmacokinetic limitations.
Clinically meaningful immunogenic, metabolic, cardiovascular, neoplastic, or other adverse signals.
Controlled canine studies showing no functional or clinical benefit despite adequate target exposure.

What could change our position

A replicated canine efficacy signal accompanied by an adequate pharmacokinetic and safety package could support movement toward veterinary_or_clinical_context.
A mature clinical-development program with compelling cross-species efficacy could strengthen the research position but would not by itself establish canine benefit.
Reproducible clinically important harm could change the position to potential_concern.

Safety and clinical context

Rodent pharmacology cannot establish canine or human safety.
FDA identified no clinical studies or human exposure data for administered MOTS-c and described potential safety risks as unknown.
Peptide immunogenicity, aggregation, impurities, and product characterization remain relevant concerns for exogenous preparations.
Endogenous presence of MOTS-c does not establish the safety of supraphysiologic or pharmaceutical administration.

Evidence record

Nara position: Clinical-trial context only
Evidence maturity: Preliminary
Most direct relevant evidence: Non-canine preclinical evidence
Overall confidence: Very low confidence
Evidence reviewed through: 2026-08-12
Assessment date: 2026-08-12
Review status: Initial Nara internal evidence assessment
Framework: Nara Evidence Framework v1.0

How Nara evaluates science

Anchor sources

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Cell Metabolism · 2015 · Mouse, rodent and human biological samples/cell systems

Primary mechanistic and mouse intervention study

Foundational MOTS-c biology and mouse metabolic intervention evidence.

10.1016/j.cmet.2015.02.009; PMID 25738459

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Nature Communications · 2021 · Mouse and human observational physiology

Primary mouse intervention and human physiological study

Reports improved physical performance and late-life physical capacity in mice; human component measures endogenous exercise responses rather than exogenous treatment efficacy.

10.1038/s41467-020-20790-0; PMID 33473109

FDA Briefing Document for MOTS-c-Related Bulk Drug Substances

U.S. FDA · 2026 · Multi-species evidence review

Regulatory scientific evidence and safety review

Finds effectiveness evidence confined to in-vitro/rodent work, no identified administered-human clinical studies, and major nonclinical and clinical safety gaps.

FDA media 193347

Your dog’s context

Bring this back to your dog.

Loading your dog’s context…